| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 238.5 | 233.1 | 202.7 |
| Other income | 4.3 | 4.6 | 4.9 |
| Total income | 242.8 | 237.7 | 207.6 |
| Profit before exceptional items & tax | 20.2 | 20.0 | 20.8 |
| Profit before tax | 20.2 | 20.0 | 20.8 |
| Net profit | 16.0 | 15.0 | 16.3 |
| Operating margin | 8.3% | 8.4% | 10.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -1.80% |
|---|---|
| Net profit, quarter on quarter | +6.70% |
| Revenue, year on year | +17.70% |
BSE results filing, NSE: WINDLAS. Figures extracted from the filing.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,102.55
- Market cap
- ₹2,314 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 34.8×Sector 50.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record annual revenue of ₹904 Cr in FY26, a 19% YoY growth, driven by its CDMO vertical. The company maintained a strong net liquidity position of ₹251 Cr with zero net debt.